Physician profile
Hussein Merza
NPI 1235409673
$9,724.71
in general payments reported to CMS, 2019-2025
62 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $804 · 2021: $3,058 · 2022: $2,568 · 2023: $2,184 · 2024: $763 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,033 · Education: $16.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,032.92 |
| Education | $16.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $968.97 | 2021-2024 | Pomalyst, Reblozyl |
| Amgen INC. | $764.94 | 2019-2023 | Kyprolis, Blincyto, Lumakras |
| Novartis Pharmaceuticals Corporation | $591.63 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $518.43 | 2020-2024 | Reblozyl, Opdivo |
| Beigene USA, INC. | $503.18 | 2020-2025 | Brukinsa |
| Janssen Biotech, INC. | $464.31 | 2020-2024 | Darzalex, Imbruvica, Tecvayli |
| Pharmacyclics LLC, An Abbvie Company | $376.18 | 2020-2023 | Imbruvica, Epkinly |
| Gilead Sciences, INC. | $351.84 | 2022-2024 | Trodelvy |
| Incyte Corporation | $344.91 | 2019-2022 | |
| Genzyme Corporation | $343.49 | 2021-2024 | |
| Pfizer INC. | $296.65 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $283.68 | 2021-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $249.09 | 2021-2025 | Zejula, Jemperli, Shingrix |
| Abbvie INC. | $243.04 | 2020-2025 | |
| Karyopharm Therapeutics INC. | $242.94 | 2020-2022 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hussein Merza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.